Our study indicated that genetic variation in SGLT2 inhibition targets was associated with a lower risk of T2DM (OR 0.63 [95% CI 0.45, 0.88], P = 0.006, per 1 SD decrement in HbA1c) and AF (0.51 [0.27, 0.97], P = 0.039). This evidence concerns the gene SLC5A2 and atrial fibrillation.